Company Overview - Celcuity Inc. is a biotechnology company focused on developing diagnostic tests for cancer patients, aiming to identify effective therapies tailored to individual needs [1] Financial Performance - Celcuity's Return on Invested Capital (ROIC) is -36.46%, significantly lower than its Weighted Average Cost of Capital (WACC) of 4.88%, indicating negative returns on invested capital [2] - The ROIC to WACC ratio for Celcuity is -7.47, showing that returns are well below the cost of capital [2] Peer Comparison - Crinetics Pharmaceuticals has a ROIC of -42.35% and a WACC of 4.55%, resulting in a ROIC to WACC ratio of -9.30, which is less negative than Celcuity's, suggesting it is closer to covering its cost of capital [3] - Evelo Biosciences has a ROIC of -201.37% and a WACC of 9.04%, leading to a ROIC to WACC ratio of -22.28, indicating a more severe situation than Celcuity [4] - Scholar Rock Holding Corporation and Cue Biopharma report negative ROICs of -101.98% and -151.57%, respectively, with ROIC to WACC ratios of -15.01 and -15.31, reflecting a common trend among clinical-stage biotech companies facing negative returns due to high R&D investments and limited revenue generation [5]

Core Insights - Vivid Seats Inc. operates in a competitive online ticket marketplace but faces significant financial challenges, particularly in capital efficiency [1][5] Financial Performance - Vivid Seats has a Return on Invested Capital (ROIC) of -61.41%, which is substantially lower than its Weighted Average Cost of Capital (WACC) of 4.95%, indicating insufficient returns to cover capital costs [2][5] - The ROIC to WACC ratio for Vivid Seats is -12.41, further emphasizing its inefficiency in capital utilization [2] - In contrast, Sovos Brands, Inc. has a positive ROIC of 5.54% and a WACC of 5.21%, suggesting effective capital use and strong financial health [3][5] - Bowlero Corp. and CareMax, Inc. both report negative ROICs of -114.39% and -117.47%, respectively, indicating similar challenges in covering their capital costs as Vivid Seats [4][5] - Stagwell Inc. shows a slightly better scenario with a positive ROIC of 3.11%, although it still does not meet its WACC of 4.11%, indicating room for improvement [4]

Core Viewpoint - Outdoor Holding Company, listed as NASDAQ:POWW, operates in the ammunition and outdoor products industry, previously known as AMMO, Inc. The company faces significant challenges in generating returns above its cost of capital compared to its competitors [1][5]. Financial Metrics - The Return on Invested Capital (ROIC) for Outdoor Holding Company is -18.08%, which is substantially lower than its Weighted Average Cost of Capital (WACC) of 9.34%, resulting in a ROIC to WACC ratio of -1.93 [2][5]. - In contrast, Smith & Wesson Brands, Inc. has a ROIC of 3.07% and a WACC of 7.53%, leading to a ROIC to WACC ratio of 0.41, indicating better capital efficiency [3][5]. - Vista Outdoor Inc. demonstrates a ROIC of 4.84% and a WACC of 7.00%, achieving the highest efficiency among peers with a ROIC to WACC ratio of 0.69 [3][5]. Peer Comparison - American Outdoor Brands, Inc. and Sportsman's Warehouse Holdings, Inc. have negative ROIC to WACC ratios of -0.47 and -0.78, respectively, but these figures are less severe than Outdoor Holding Company's -1.93 [4][5]. - Sturm, Ruger & Company, Inc. has a positive ROIC to WACC ratio of 0.15, indicating some level of efficiency in generating returns above its cost of capital [4].

Core Insights - International Seaways, Inc. (NYSE:INSW) is a significant entity in the shipping industry, focusing on crude oil and petroleum product transportation, with a diverse fleet for global energy resource delivery [1] - The company's Return on Invested Capital (ROIC) is 8.85%, while its Weighted Average Cost of Capital (WACC) is 5.07%, resulting in a favorable ROIC to WACC ratio of 1.75, indicating effective capital utilization [2][5] Peer Comparison - Scorpio Tankers Inc. has a ROIC of 8.01% and a WACC of 6.13%, leading to a ROIC to WACC ratio of 1.31, which is lower than INSW's [3] - Euronav N.V. shows a higher ROIC of 18.03% against a WACC of 6.98%, achieving a ratio of 2.58, indicating superior capital efficiency compared to INSW [3] - Ardmore Shipping Corporation's ROIC is 10.33% with a WACC of 5.38%, resulting in a ratio of 1.92, also above Scorpio Tankers but below Euronav [3] - Teekay Tankers Ltd. leads the group with a ROIC of 12.88% and a WACC of 4.77%, achieving the highest ROIC to WACC ratio of 2.70, indicating the most efficient capital utilization among peers [4][5] - Dorian LPG Ltd. has a ROIC of 4.18% and a WACC of 6.25%, resulting in a ratio of 0.67, indicating it is generating returns below its cost of capital [4][5]

Core Insights - Coeptis Therapeutics, Inc. is facing significant challenges in capital utilization and return generation within the competitive biotechnology sector [1] - The company's Return on Invested Capital (ROIC) is -91.29%, while its Weighted Average Cost of Capital (WACC) is 5.55%, leading to a negative ROIC to WACC ratio of -16.45, indicating inefficiencies in capital utilization [2] - In contrast, ZyVersa Therapeutics, Inc. demonstrates strong capital efficiency with a positive ROIC of 220.45% and a WACC of 7.54%, resulting in a favorable ROIC to WACC ratio of 29.23 [4] Company Comparisons - Cardio Diagnostics Holdings, Inc. has a ROIC of -60.70% and a WACC of 16.84%, yielding a less severe ROIC to WACC ratio of -3.60 compared to Coeptis [3] - SeaStar Medical Holding Corporation and Dermata Therapeutics, Inc. also report negative ROICs of -121.49% and -194.54%, respectively, with ROIC to WACC ratios of -7.04 and -31.71, highlighting similar challenges in generating returns above their cost of capital [5]

Vyome Holdings, Inc. (HIND) exhibits a significantly negative Return on Invested Capital (ROIC) of -369.22%, indicating poor capital utilization.Digital Brands Group, Inc. (DBGI) shows the least negative ROIC to WACC ratio among peers, suggesting relatively better capital efficiency.Several companies within the same industry, including Palisade Bio, Inc. (PALI) and Ensysce Biosciences, Inc. (ENSC), also struggle with negative ROIC, highlighting potential industry-wide challenges.Vyome Holdings, Inc. (HIND) ...

Immunocore's Return on Invested Capital (ROIC) is -4.49% and its Weighted Average Cost of Capital (WACC) is 6.65%, indicating it is not generating returns above its cost of capital.Compared to its peers, Immunocore has a better ROIC to WACC ratio, suggesting relatively more efficient capital utilization.Design Therapeutics, Inc. (DSGN) has the highest ROIC to WACC ratio among the peers, although it is still negative, highlighting the broader industry challenge of achieving positive returns on invested capit ...

Phunware's Return on Invested Capital (ROIC) is -17.56%, indicating it is not generating sufficient returns to cover its cost of capital.Remark Holdings, Inc. (NASDAQ:MARK) and Exela Technologies, Inc. (NASDAQ:XELA) show positive ROIC, highlighting more effective capital utilization.Phunware's significantly negative ROIC compared to peers suggests a need for strategic improvements in capital efficiency.Phunware, Inc. (NASDAQ:PHUN) is a technology company that provides a fully integrated enterprise cloud pla ...

Core Insights - Editas Medicine, Inc. is a biotechnology company focused on developing gene editing technologies, specifically utilizing its proprietary CRISPR technology to create transformative medicines [1] - Editas competes with other companies in the gene editing sector, including Intellia Therapeutics, CRISPR Therapeutics, Beam Therapeutics, and Pacific Biosciences of California [1] Financial Performance - Editas Medicine's Return on Invested Capital (ROIC) is -154.03%, which is significantly lower than its Weighted Average Cost of Capital (WACC) of 13.54%, indicating insufficient returns on invested capital [2] - The ROIC to WACC ratio for Editas is -11.38, highlighting a concerning disparity between returns and capital costs [2] - In comparison, Intellia Therapeutics has a ROIC of -42.76% and a WACC of 11.66%, resulting in a less severe ROIC to WACC ratio of -3.67, suggesting slightly better capital efficiency [3] - CRISPR Therapeutics has a ROIC of -23.46% and a WACC of 11.43%, with the best ROIC to WACC ratio among peers at -2.05, indicating relatively better capital management [3] - Beam Therapeutics and Pacific Biosciences report negative ROICs of -40.86% and -86.29%, respectively, with ROIC to WACC ratios of -3.07 and -10.68, reflecting challenges in generating returns above their capital costs [4] - Overall, all companies in the gene editing space, including Editas, face difficulties in achieving returns above their cost of capital [5]

Greenpro Capital Corp. (NASDAQ:GRNQ) faces significant challenges with a ROIC of -24.25% compared to its WACC of 11.57%, indicating inefficiencies in generating sufficient returns.Senmiao Technology Limited (NASDAQ:AIHS) exhibits a more concerning scenario with a ROIC of -622.64% against a WACC of 7.78%, highlighting severe capital utilization issues.Farmmi, Inc. (NASDAQ:FAMI) and Oxbridge Re Holdings Limited (NASDAQ:OXBR) also show negative ROIC figures, but Farmmi's closer-to-neutral ROIC to WACC ratio su ...